| Mr James A Sabetta, PAC | |
|
3975 Embassy Pkwy, Akron, OH 44333-8320 | |
| (330) 668-4040 | |
| (330) 668-4078 |
| Full Name | Mr James A Sabetta |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 17 Years |
| Location | 3975 Embassy Pkwy, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972584605 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AS0400X | Physician Assistant - Surgical | 50.001489RX (* (Not Available)) | Primary |
| 207P00000X | Emergency Medicine | 50001489 (Ohio) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Crystal Clinic Orthopaedic Center | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crystal Clinic Orthopaedic Center, Llc | 6507934015 | 38 |
| Crystal Clinic, Inc. | 7214821586 | 48 |
News Archive
Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Genetic variation in patients with inflammatory bowel disease (IBD) appears to play a major role in determining how sick they will become and could provide a road map for more effective treatments.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr James A Sabetta, PAC 3975 Embassy Pkwy, Akron, OH 44333-8320 Ph: (330) 668-4040 | Mr James A Sabetta, PAC 3975 Embassy Pkwy, Akron, OH 44333-8320 Ph: (330) 668-4040 |
News Archive
Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA).
Genetic variation in patients with inflammatory bowel disease (IBD) appears to play a major role in determining how sick they will become and could provide a road map for more effective treatments.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
› Verified 2 days ago
Margaret S Sfiligoj, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-9634 Fax: 330-375-3769 | |
Brittany Johnson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1622 E Turkeyfoot Lake Rd Ste 201, Akron, OH 44312 Phone: 330-776-4444 Fax: 330-776-4449 | |
Brittany Conner, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3975 Embassy Pkwy, Akron, OH 44333 Phone: 330-670-4242 | |
Mrs. Lara Renee Young, P.A.-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 150 Cross St, Akron, OH 44311 Phone: 330-996-9141 | |
Mr. Kodi Veale, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3975 Embassy Pkwy, Akron, OH 44333 Phone: 330-668-4040 Fax: 330-668-4078 | |
Eric Bendel, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Christy A. Mackay, PAC Physician Assistant Medicare: Medicare Enrolled Practice Location: 1 Park West Blvd, Suite 200, Akron, OH 44320 Phone: 330-869-9777 Fax: 330-865-6011 |